ArticleBMC cancer2025
DWI-guided DP-IMRT and conventional MRI-based IMRT in head and neck squamous cell carcinoma: a comparative study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThe impact of diffusion-weighted magnetic resonance imaging guided dose-painting intensity-modulated radiation therapy on head and neck squamous cell carcinoma remains unclear. Our objective aimed at comparing the outcomes and toxicities of DWI-guided DP-IMRT for HNSCC. METHODS AND MATERIALS: Between June 2018 and November 2022, we conducted a retrospective analysis of 260 HNSCC patients. Among them, 126 received chemoradiotherapy using DWI-guided dose painting intensity-modulated radiation therapy (DWI group), and the remaining 134 underwent chemoradiotherapy using conventional MRI-based intensity-modulated radiation therapy (Standard group). In DWI group, DW-MRI-guided gross tumor volume (GTV) received escalation to 77 Gy/35 fx in 2.2 Gy per fraction, while in Standard group, the GTV of HNSCC was irradiated at 70 Gy/35 fx at 2.0 Gy per fraction. All patients received induction chemotherapy. Survival rates were compared, and multivariate analyses were conducted.
resultsThe median follow-up duration was 23 months. Compared to conventional MRI-based intensity-modulated radiation therapy, DWI-guided dose painting intensity-modulated radiation therapy showed improved 2-year disease-free survival (75.2% vs. 63.8%; P =.011) and locoregional recurrence-free survival (75.9% vs.64.7%; P =.013). Overall survival did not show significant difference between DWI group and Standard group (P =.442). Grade 3-5 toxicities were similar between the two groups. Multivariate analysis showed that DWI-guided dose painting was an independent prognostic factor for DFS (HR 0.559, 95% CI 0.324-0.966, P =.037).
conclusionDWI-guided dose escalation has a benefit in DFS for patients with HNSCC without increasing acute adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.